Fresenius & KGaA ADR Logo
US35804M1053
A1XCZQ
FSNUY

Fresenius & KGaA ADR

Loading quotes...

Forecast

The analysts' average price target is €8.45 (-39.86%). The median is €8.45 (-39.86%).

Buy
  1
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics
In 2026, Fresenius & KGaA ADR has already paid €0.26 in dividends. The last payout was in June.

Financials

In the last quarter, Fresenius & KGaA ADR had revenue of €5.88B and net profit of €371M
(EUR) September 2026
YoY
Revenue 5.88B 7.53%
Gross profit 1.53B 18.20%
Net profit 371M 8.10%
EBITDA 848M 10.38%

Fundamentals

Metric Value
Market capitalization
€121.15B
Number of shares
9.01B
52-week high/low
€14.48 - €9.38
Dividend yield
1.97%
Dividends TTM
€0.26
Beta
0.83
P/E ratio
19.15
PEG ratio
0.51
P/B ratio
1.47
P/S ratio
1.27

Company profile

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Name
Fresenius & KGaA ADR
CEO
Michael Sen
Headquarters Bad Homburg vor der Höhe, he
Germany
Website
IPO
05/15/2012
Employees 178,394

Ticker symbols

Exchange Symbol
Pnk
FSNUY
Frankfurt
FREA.F
München
FREA.MU
🍪

Parqet  uses cookies. Learn more